1. Home
  2. SKT vs ADMA Comparison

SKT vs ADMA Comparison

Compare SKT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKT

Tanger Inc.

HOLD

Current Price

$36.01

Market Cap

3.7B

Sector

Real Estate

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$15.38

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKT
ADMA
Founded
1981
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.6B
IPO Year
1994
2012

Fundamental Metrics

Financial Performance
Metric
SKT
ADMA
Price
$36.01
$15.38
Analyst Decision
Hold
Strong Buy
Analyst Count
7
2
Target Price
$37.29
$28.50
AVG Volume (30 Days)
1.0M
3.0M
Earning Date
05-27-2026
05-15-2026
Dividend Yield
3.18%
N/A
EPS Growth
N/A
N/A
EPS
0.71
0.60
Revenue
N/A
$42,219,783.00
Revenue This Year
N/A
$26.71
Revenue Next Year
$5.17
$21.78
P/E Ratio
$51.86
$25.99
Revenue Growth
N/A
43.85
52 Week Low
$28.69
$13.76
52 Week High
$37.95
$25.67

Technical Indicators

Market Signals
Indicator
SKT
ADMA
Relative Strength Index (RSI) 55.81 40.86
Support Level $31.76 $15.35
Resistance Level $37.95 $16.28
Average True Range (ATR) 0.80 0.86
MACD 0.05 0.05
Stochastic Oscillator 50.51 32.18

Price Performance

Historical Comparison
SKT
ADMA

About SKT Tanger Inc.

Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: